Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × anlotinib × Gynecologic × Clear all

Phase

Status

Unknown 8 Recruiting 2 Withdrawn 1 Terminated 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 10 Gastrointestinal 7 Tumor-Agnostic 3 Head & Neck 3 Breast 2 Other solid neoplasm 1 Gynecologic 1 CNS 1

Conditions

Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1

Interventions

Paclitaxel 231 Carboplatin 219 Cisplatin 137 Bevacizumab 93 Topotecan 70 Gemcitabine 68 liposomal doxorubicin 57 pembrolizumab 50 Docetaxel 49 Cyclophosphamide 48 Doxorubicin 43 Taxes 41 Radiotherapy 41 Surveys and Questionnaires 40 Filgrastim 37 Brachytherapy 35 olaparib 34 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 24 Drug Therapy 24 Blood Specimen Collection 24 niraparib 22 human papillomavirus vaccine, L1 type 16, 18 22 Peripheral Blood Stem Cell Transplantation 21 Nivolumab 20 Hyperthermic Intraperitoneal Chemotherapy 20 Pemetrexed 19 Oxaliplatin 19 Etoposide 19 atezolizumab 18 Radiation 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130515 2023-01-31

CC-ANNIE

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Completed

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡